Founded in 1928 in Brussels, Belgium, by Emmanuel Janssen as Union Chimique Belge, UCB has evolved from its industrial chemical origins into a global biopharmaceutical company focused on severe diseases of the immune and central nervous systems. Headquartered in Brussels, the company has built a strong international position through long-term scientific investment, a differentiated portfolio in neurology and immunology, and a clear patient-centered approach to innovation. UCB operates in approximately 40 countries and employs 10,117 people worldwide in 2025. For the full year 2025, the company reported revenue of EUR 7.741 billion, reflecting a business of growing scale and increasing global relevance in specialty biopharmaceuticals.
Updated 2026-03-19